Cynthia Chmielewski | CureTalks
Cynthia attended Rutgers University graduating with degrees in Psychology and Education. Upon graduation she secured her first teaching position and immediately fell in love with her chosen profession. Cynthia continued teaching for 28 years. Now retired, Cynthia, a myeloma survivor, is using her passion for education to teach a new group of "students" - myeloma patients and their caregivers. She is on the advisory boards of the Patient Empowerment Network, the Myeloma Crowd and the Philadelphia Multiple Myeloma Networking Group. Using social media to educate is her passion. Cynthia educates and advocates by tweeting at @MyelomaTeacher and sharing myeloma resources, educational opportunities and clinical trial information on her MyelomaTeacher Facebook page. Ms. Chmielewski is the co-founder of the #MMSM TweetChat and is also a regular panelist on CureTalks Podcast. Cynthia was an invited panelist and presented posters on using social media in hematology at the annual meetings of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR) and the European Bone Marrow Transplant (EBMT). More recently Cynthia joined the Patient Engagement team at Patient Power. Additionally, she consults on educational projects sponsored by the Myeloma Crowd. She enjoys serving as a voting member on the IRB at the University of Pennsylvania, a peer reviewer for the NCI’s DEA grants program and a patient advocate on the Myeloma Steering Committee of the National Cancer Institute (NCI) and ACCRU. Cynthia has also participated in the Department of Defense’s CMCRP grant reviews.
Related Talks
ASH 2019 Annual Meeting Multiple Myeloma Updates
The 62nd ASH (American Society of Hematology) annual meeting was held in early December 2019. We are talking to Dr Shaji Kumar about…
Multiple Myeloma Stem Cells and Drug Resistance in Myeloma Management
Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although…
Understanding the FDA approved New Drug, Selinexor and its Use in Multiple Myeloma
Recently, the FDA approved a new cancer drug called Selinexor. This drug has been found to be successful in treating multiple myeloma in…
Treatments for Early Stage Plasma Cell Disorders
Plasma cell disorders like multiple myeloma, plasmacytoma, smoldering myeloma, MGUS are diseases in which the body makes too many plasma cells. These disorders…
ASCO 2019 Highlights: Advances in Multiple Myeloma
ASCO 2019 conluded on 4th June 2019 and we are excited about Multiple Myeloma updates from the largest gathering of oncologists, researchers and…